Thompson Peter A.
SEC-identified person · CIK 1357522 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Silverback Therapeutics, Inc. SPRY | Director | filed 2020–2026 |
| Sionna Therapeutics, Inc. SION | Director | filed 2025–2026 |
| Edgewise Therapeutics, Inc. EWTX | Director | filed 2021–2026 |
| Corvus Pharmaceuticals, Inc. CRVS | Director | filed 2016–2026 |
| Nivalis Therapeutics, Inc. NVLS | Director | filed 2017–2024 |
| Decibel Therapeutics, Inc. [DBTX] | Director | filed 2021–2022 |
| Janux Therapeutics, Inc. JANX | Director | filed 2021–2022 |
| PMV Pharmaceuticals, Inc. PMVP | Director | filed 2020–2021 |
| Prevail Therapeutics Inc. PRVL | Director | filed 2019–2021 |
| Synthorx, Inc. THOR | Director | filed 2018–2020 |
| Principia Biopharma Inc. PRNB | Director | filed 2018–2018 |
| Adaptimmune Therapeutics PLC ADAP] | Director | filed 2016–2018 |
| Response Biomedical Corp RBM | Director · Interim Chief Exec Officer | filed 2012–2016 |
| Sierra Oncology, Inc. SRRA | Director | filed 2015–2015 |
| Mirati Therapeutics, Inc. mrtx | Director | filed 2013–2013 |
| Anthera Pharmaceuticals Inc ANTH | Director | filed 2011–2012 |
| Trubion Pharmaceuticals, Inc TRBN | Director · President, CEO & Treasurer | filed 2006–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.